SGLT2 inhibitors: diabetic kidney disease and beyond.
作者信息
Staruschenko Alexander, Bhalla Vivek, Rangaswami Janani
机构信息
Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Clement J. Zablocki Vetarans Affairs Medical Center, Milwaukee, Wisconsin.
出版信息
Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F780-F781. doi: 10.1152/ajprenal.00518.2020. Epub 2020 Oct 5.
Abstract
摘要
相似文献
1
SGLT2 inhibitors: diabetic kidney disease and beyond.钠-葡萄糖协同转运蛋白2抑制剂：糖尿病肾病及其他
Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F780-F781. doi: 10.1152/ajprenal.00518.2020. Epub 2020 Oct 5.
2
Effects of sodium glucose co-transporter 2 inhibitors on the kidney.钠-葡萄糖协同转运蛋白2抑制剂对肾脏的影响。
Diab Vasc Dis Res. 2018 Sep;15(5):375-386. doi: 10.1177/1479164118783756. Epub 2018 Jul 2.
3
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.扩大钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病中的影响
Am J Nephrol. 2024;55(4):417-420. doi: 10.1159/000536540. Epub 2024 Feb 28.
4
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.SGLT2 抑制剂对 2 型糖尿病合并慢性肾脏病患者心血管、肾脏和安全性结局的影响：系统评价和荟萃分析。
Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.
5
How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?CREDENCE研究如何为CKD中SGLT2抑制剂的最佳使用提供信息？
Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1667-1669. doi: 10.2215/CJN.05340419. Epub 2019 Oct 1.
6
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.用于治疗糖尿病肾病的 SGLT2 抑制剂和 GLP-1 受体激动剂的处方决策算法。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688. doi: 10.2215/CJN.02690320. Epub 2020 Jun 9.
7
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.SGLT2 抑制剂在 2 型糖尿病合并肾脏疾病患者中的应用：现有证据概述。
Postgrad Med. 2019 May;131(4):251-260. doi: 10.1080/00325481.2019.1601404. Epub 2019 Apr 14.
8
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病肾病的肾脏保护作用及其机制。
J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5.
9
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
10
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.慢性肾脏病中的钠-葡萄糖协同转运蛋白2抑制剂
ScientificWorldJournal. 2015;2015:317507. doi: 10.1155/2015/317507. Epub 2015 Feb 15.
引用本文的文献
1
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.尽管有明确的实用证据，但对《2012年改善全球肾脏病预后组织慢性肾脏病临床实践指南》的依从性较低。
Kidney Int Rep. 2022 Jun 8;7(9):2059-2070. doi: 10.1016/j.ekir.2022.05.033. eCollection 2022 Sep.
2
SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na transport in Dahl SS rats.SGLT2 抑制剂对 SS 大鼠盐诱导性高血压、肾素-血管紧张素-醛固酮系统和钠转运的影响。
Am J Physiol Renal Physiol. 2022 Jun 1;322(6):F692-F707. doi: 10.1152/ajprenal.00053.2022. Epub 2022 Apr 25.
本文引用的文献
1
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.新型抗糖尿病药物在糖尿病合并慢性肾脏病患者中的心脏肾脏保护作用：美国心脏协会的科学声明。
Circulation. 2020 Oct 27;142(17):e265-e286. doi: 10.1161/CIR.0000000000000920. Epub 2020 Sep 28.
2
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
3
Advancing Nephrology: Division Leaders Advise ASN.推进肾脏病学发展：部门领导为美国肾脏病学会建言献策。
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):319-327. doi: 10.2215/CJN.01550220. Epub 2020 Aug 12.
4
The tubular hypothesis of nephron filtration and diabetic kidney disease.管状假说在肾单位滤过和糖尿病肾病中的作用。
Nat Rev Nephrol. 2020 Jun;16(6):317-336. doi: 10.1038/s41581-020-0256-y. Epub 2020 Mar 9.
5
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.在糖尿病肾病试验中评估非奈利酮降低肾衰竭和疾病进展风险的设计和基线特征。
Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
7
Development of SGLT1 and SGLT2 inhibitors.SGLT1 和 SGLT2 抑制剂的研发。
Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22.
8
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.抗高血糖药物在糖尿病肾病中的新型利钠治疗作用。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1406-F1415. doi: 10.1152/ajprenal.00384.2017. Epub 2018 Aug 1.
9
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Zotero 插件